An independent committee has
recommended that a late (Phase
III) stage study of a drug developed
by Pharmacyclics and Johnson
& Johnson be stopped early due
to improved overall survival in
patients with chronic lymphocytic
leukemia (CLL).
The drug IMBRUVICA (ibrutinib)
showed a “statistically significant
improvement in progression-free
survival” as well as overall survival
in patients with relapsed or
refractory CLL or small lymphocytic
lymphoma (SLL).
The study involved 391 patients
and was conducted at more than
70 clinical sites in 10 countries,
Pharmacyclics said.
To read more CLICK HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 08 Jan 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Jan 14
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.